GenoMed Trial Results: HIV -- Viral Load Goes to Zero
ST. LOUIS, Feb. 21 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED), a Next Generation Disease Management company whose business is public health, announced today that its first HIV patient had his viral load fall to zero after starting GenoMed's trial.
The patient is a 54 year old African American man who was diagnosed with HIV 2 years ago. He was being treated with a standard triple-drug 'cocktail' and had a stable viral load when he began GenoMed's trial this past summer, as shown in the following table:
Date HIV viral load (copies of the virus per milliliter)
4/11/05 160
6/23/05 228
7/19/05 225
8/29/05 START OF GenoMed's TRIAL
11/2005 0
12/2005 0
1/2006 Switch from Sustiva(R) to Kaletra(R), which had failed this
patient in the past
2/14/06 109
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, 'In this trial, we've been using blood pressure pills, for which we have a 'use' patent that is pending. Why this should work is as interesting as the fact that it has worked. It points out the clinical reliability of the genomic epidemiologic data that we published in 2002.'
Continued Dr. Moskowitz, 'Our approach, if it is confirmed in other HIV patients, may help with the chronic treatment of HIV patients. Our earlier data suggests that this approach may also decrease infectivity of the HIV virus in the first place. Because these drugs already are on the shelves in most pharmacies on earth, including Africa, it could be quite helpful in the global struggle against HIV/AIDS.' |
